Nuveen Asset Management LLC Sells 75,257 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Nuveen Asset Management LLC lowered its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 20.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 288,378 shares of the biopharmaceutical company's stock after selling 75,257 shares during the quarter. Nuveen Asset Management LLC owned about 0.43% of Celldex Therapeutics worth $7,287,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of CLDX. Barclays PLC lifted its holdings in Celldex Therapeutics by 140.7% in the third quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company's stock worth $4,431,000 after purchasing an additional 76,207 shares during the period. SG Americas Securities LLC lifted its holdings in Celldex Therapeutics by 24.4% in the fourth quarter. SG Americas Securities LLC now owns 25,283 shares of the biopharmaceutical company's stock worth $639,000 after purchasing an additional 4,967 shares during the period. KBC Group NV lifted its holdings in Celldex Therapeutics by 79.1% in the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after purchasing an additional 1,647 shares during the period. Sovran Advisors LLC acquired a new stake in Celldex Therapeutics in the fourth quarter worth about $2,867,000. Finally, Values First Advisors Inc. lifted its holdings in Celldex Therapeutics by 20.0% in the fourth quarter. Values First Advisors Inc. now owns 29,009 shares of the biopharmaceutical company's stock worth $733,000 after purchasing an additional 4,837 shares during the period.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on CLDX shares. The Goldman Sachs Group reduced their price objective on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Morgan Stanley cut their price objective on Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. Canaccord Genuity Group initiated coverage on Celldex Therapeutics in a report on Monday, April 28th. They set a "buy" rating and a $64.00 price objective on the stock. UBS Group dropped their target price on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Finally, HC Wainwright reiterated a "buy" rating and issued a $80.00 target price on shares of Celldex Therapeutics in a report on Tuesday, May 6th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Celldex Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $53.90.

Celldex Therapeutics Stock Performance

Shares of NASDAQ CLDX traded down $0.35 during trading hours on Friday, hitting $19.49. The stock had a trading volume of 923,822 shares, compared to its average volume of 912,883. The company has a market capitalization of $1.29 billion, a P/E ratio of -7.58 and a beta of 1.39. The firm's 50-day moving average price is $18.87 and its two-hundred day moving average price is $22.18. Celldex Therapeutics, Inc. has a 52 week low of $14.40 and a 52 week high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). The firm had revenue of $0.70 million during the quarter, compared to the consensus estimate of $1.08 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. As a group, analysts expect that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.